Dupixent maintains long-term safety, efficacy in patients with EoE

CHARLOTTE, N.C. — Dupilumab maintains its safety and efficacy for up to 52 weeks in patients with eosinophilic esophagitis, according to late-breaking data from the phase 3 LIBERTY EoE TREET study presented at ACG Annual Scientific Meeting.“As this audience knows, EoE is a chronic, progressive type 2 inflammatory disease of the esophagus, and current treatment options lack specificity and present adherence challenges,” Evan S. Dellon, MD, MPH, FACG, professor of medicine and adjunct professor of epidemiology in the Center for Esophageal Diseases and Swallowing at theRead More